(19)

(11)

EP 4 487 310 A2

(12)

(88) Date of publication A3: 12.10.2023 (43) Date of publication: 08.01.2025 Bulletin 2025/02 (21) Application number: 23764059.4 (22) Date of filing: 01.03.2023

(51) International Patent Classification (IPC):  G07F 17/32(2006.01) G06Q 50/34(2012.01) G06N 20/00(2019.01) (52) Cooperative Patent Classification (CPC): G07F 17/3288; G07F 17/3262 (86) International application number: PCT/US2023/063439 (87) International publication number: WO 2023/168236 (07.09.2023 Gazette 2023/36)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 01.03.2022 US 202217683793 (71) Applicant: ADRENALINEIP Washington, DC 20007 (US)	(72) Inventors: HUKE, Casey, Alexander Washington, DC 20007 (US) CRONIN, John Jericho, VT 05465 (US) BODKIN, Joseph Quincy, MA 02170 (US) GRANT, Harrison Anaheim, CA 92802 (US) (74) Representative: Botti & Ferrari S.p.A.  Via Cappellini, 11 20124 Milano 20124 Milano (IT)